National Academies Press: OpenBook
« Previous: Appendix A: Workshop Agenda
Suggested Citation:"Appendix B: Polling Results." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×

Appendix B
Polling Results

At two points during the conference, participants attending the workshop in person were given individual keypads to respond to a series of questions posed by John Wagner, chair of the workshop planning committee. He noted that he was sampling a very small population (22 responses were obtained) biased toward seeing the value to collaborations, so the results featured below, though of interest, are by no means scientific or representative of the community of biomedical researchers.

Questions

Responses

Percentage

Count

What organization do you represent?

Government

0

0

Industry

32

7

Academia

18

4

Nonprofit

23

5

Other

27

6

Have you personally participated in a precompetitive collaboration?

Yes

52

11

No

48

10

Has your institution/company participated in a precompetitive collaboration?

Yes

77

17

No

23

5

Suggested Citation:"Appendix B: Polling Results." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×

Questions

Responses

Percentage

Count

How important do you feel precompetitive collaboration is to biomedical research?

Not at all important

5

1

Somewhat important

0

0

Important

5

1

Very important

23

5

Critical

68

15

Which research activity do you feel can benefit most from precompetitive collaboration?

Bioinformatics/software development

4

1

Data generation/collection efforts

35

8

Basic research

17

4

Translational/disease-focused research

35

8

Product-oriented research

9

2

What do you see as the biggest hurdle to precompetitive collaboration in biomedicine?

Individualist/competitive culture among academics

30

6

Proprietary culture of industry

25

5

Intellectual property issues

25

5

Academic promotion/tenure process

15

3

Publications

0

0

Patient privacy concerns

5

1

How relevant/applicable are industry collaborations, such as SEMATECH, to biomedical research?

Not at all important

0

0

Somewhat important

16

3

Important

16

3

Very important

42

8

Critical

26

5

How relevant/applicable are prizes, such as InnoCentive offers, to biomedical research?

Not at all important

0

0

Somewhat important

42

8

Important

26

5

Very important

21

4

Critical

11

2

Suggested Citation:"Appendix B: Polling Results." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×

Questions

Responses

Percentage

Count

How relevant/applicable are True Open Source Collaborations, such as Linux, to biomedical research?

Not at all important

0

0

Somewhat important

26

5

Important

26

5

Very important

21

4

Critical

26

5

Suggested Citation:"Appendix B: Polling Results." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×

This page intentionally left blank.

Suggested Citation:"Appendix B: Polling Results." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×
Page 95
Suggested Citation:"Appendix B: Polling Results." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×
Page 96
Suggested Citation:"Appendix B: Polling Results." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×
Page 97
Suggested Citation:"Appendix B: Polling Results." Institute of Medicine. 2010. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12930.
×
Page 98
Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary Get This Book
×
 Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary
Buy Paperback | $41.00 Buy Ebook | $32.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Despite spending more time and money in developing novel therapeutics, the success rate for new pharmacologic treatments has been poor. Although the research and development expenditures have grown 13 percent each year since 1970 (a 50-fold increase), the number of new drugs approved annually is no greater now than it was 50 years ago. Over the past decade, skyrocketing costs and the complexity of the scientific knowledge upon which to develop new agents have provided incentives for alternative approaches to drug development, if we are to continue to improve clinical care and reduce mortality. These challenges create opportunities for improved collaboration between industry, academia, government, and philanthropic organizations at each stage in new drug development, marketing, and implementation.

Perhaps the most appropriate initial step in addressing the need for collaboration is to consider more precompetitive relationships that allow sharing of scientific information to foster drug development. While these collaborative relationships in basic and preclinical research on drug targets and the early stages of clinical testing are acknowledged to be potentially important drivers for innovation and more rapid marketing of new agents, they also raise a number of concerns that must be addressed. For example, acknowledgment of academic productivity and independence and economic competitiveness must be considered and these challenges managed to foster a culture of collaboration. At the same time, regulatory issues, the need for standardization, and intellectual property concerns must be confronted if the current models for drug development are to be refined to encourage robust participation in precompetitive collaborations.

Recognizing the growing importance of precompetitive collaborations in oncology drug development, as well as the challenges these innovative collaborations pose, the National Cancer Policy Forum of the Institute of Medicine held a workshop on February 9 and 10, 2010. This book is a summary of the workshop proceedings.

READ FREE ONLINE

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!